Observational Study Journal Article Ppublish 7 citations
PubMed: 35790875 DOI: 10.1038/s41371-022-00716-7
The effects of antihypertensive medications on severity and outcomes of hypertensive patients with COVID-19.
J Hum Hypertens 37(7):511-518
Authors: Samira Nakhaie, Rostam Yazdani, Mohammadreza Shakibi, Soheila Torabian, Sara Pezeshki, Maliheh Sadat Bazrafshani, Maryam Azimi, Faranak Salajegheh
Affiliations
- Endocrinology and Metabolism Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran.
- HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.
- Department of Traditional Medicine, School of Traditional Medicine, Kerman University of Medical Sciences, Kerman, Iran.
- Endocrinology and Metabolism Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran.
Abstract
In Covid-19 pandemic, specific comorbidities are associated with the increased risk of worse outcomes and increased severity of lung injury and mortality. the aim of this study was to investigate the effects of antihypertensive medications on the severity and outcomes of hypertensive patients with COVID-19. This retrospective observational study conducted on patients with COVID-19 who referred to Afzalipour Hospital, Kerman, Iran during the six months from 19 February 2020 to 20 July 2020. The data were collected through medical chart reviews. We assessed 265 patients with Covid-19 and they stratified based on hypertension and type of antihypertension medications. The data were described and Student's t-test, Mann-Whitney U and Fisher exact test were run to compare the patients 'demographical and clinical information. The qualitative variables were compared using the by SPSS software version 23. The results of the present study showed that hypertension was a prevalent comorbidity among patients with COVID-19 and hypertensive patients compared to other patients without any comorbidity who were older (P-value: 0.03). The oxygen saturation was higher for the patients in the control group than hypertensive patients (P-value: 0.01). The severity of COVID-19 and its outcome were not different between the patients who took or did not take antihypertensive medications and also the type of antihypertensive medications. Hypertensive patients did not show any significant difference in survival, hospital stay, ICU admission, disease severity, and invasive medical ventilation in other normotensive patients with COVID-19.
MeSH
Comorbidity, Hypertension, Antihypertensive Agents, Covid-19
Cited by
- The effects of antihypertensive medications on severity and outcomes of COVID19. J Hum Hypertens, 2022
- Impact and prevalence of comorbidities and complications on the severity of COVID-19 in association with age, gender, obesity, and pre-existing smoking: A meta-analysis. Biomedicine (Taipei), 2024
- Impact of Hypertension and Antihypertensive Treatment on COVID-19 Severity: A Retrospective Observational Study in Ternopil Region, Ukraine. Ther Clin Risk Manag, 2025
- Omics for searching plasma biomarkers associated with unfavorable COVID-19 progression in hypertensive patients. Sci Rep, 2025
- Insights into COVID-19: Perspectives on Drug Remedies and Host Cell Responses. Biomolecules, 2023